NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nocion Therapeutics

Nocion Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://www.nociontx.com/

Last Round

Early Stage

VC

Mar 13, 2026

Est. Valuation

$125M

Total Funding Raised

$166M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nocion Therapeutics is a biopharmaceutical company developing a new class of small molecule charged sodium channel blockers, called nocions, to treat conditions such as chronic cough, pain, and itch.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

charged sodium channel blockersCSCBschronic cough treatmentnocionsTaplucainiuminhaled therapyrefractory chronic coughclinical stage companysensory neuron hypersensitivitysmall molecule therapynociceptor targetingfirst-in-class therapynon-opioid pain therapydry powder inhalerrCC/uCCitch treatmentneurogenic inflammation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nocion Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Nocion Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Nocion Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCMar 13, 2026
Series B ExtensionJan 7, 2026
Series BMar 4, 2024
Series AJan 25, 2021
Series AApr 17, 2019
Seed
Jul 10, 2018

Key People

Founding team and executive leadership

Rick Batycky

President CEO

Executive Team

Nocion Therapeutics Investors

Notable investors and investment history

Nocion Therapeutics investors
InvestorRounds
F-Prime CapitalSeries B, Series B Extension, Series A
Mass General Brigham InnovationSeries B Extension, Series B, Series A
Mass General Brigham VenturesSeries B Extension
Osage University PartnersSeries B, Series B Extension
BioInnovation CapitalSeries B, Series A, Series B Extension
Monograph CapitalSeries B, Series B Extension
Canaan PartnersSeries B, Seed, Series A, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 7, 2026

    $23M raised in Series B Extension round.

  • Apr 28, 2025

    Matthew Frankel, M.D., MBA appointed as Chief Medical Officer.

Nocion Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nocion Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nocion Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range19
Year Founded2017
Last FundingMar 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.